- Home
- BRNS vs TCRX Comparison
BRNS vs TCRX Comparison
Compare BRNS & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRNS | TCRX |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 64.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BRNS | TCRX |
|---|---|---|
| Price | $0.69 | $1.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $4.00 | ★ $8.50 |
| AVG Volume (30 Days) | 101.8K | ★ 823.7K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,423,000.00 |
| Revenue This Year | N/A | $286.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1766.46 | N/A |
| 52 Week Low | $0.64 | $0.91 |
| 52 Week High | $2.92 | $3.43 |
Technical Indicators
Market Signals| Indicator | BRNS | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.40 | 39.94 |
| Support Level | $0.66 | $0.99 |
| Resistance Level | $0.78 | $1.09 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 7.88 | 35.71 |
Price Performance
Historical ComparisonAbout BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.